Creative Medical Technology Holdings Inc (CELZ)

[stervc]

soupoftheday, why a CELZ valuation is hard & more...

It's kind of hard to gather a valuation for CELZ because what they have could potentially save lives. There is no price for life. I believe people will pay whatever the cost of money to save their lives. That's why it's kind of hard with biotech/medical stocks without seeing the pricing delivered from the company for its treatment. With CELV, they also have much more than just the patent to reverse liver failure. Although they just filed it, it's considered "patent pending" so they still can move forward with having the rights as if they have the patent. They do have a patent from positive preclinical data for treatment of strokes with using their ImmCelz® cell based immunotherapy. They have patents for stem cell treatments, and much more. Here are some of their patents/intellectual property within their pipeline within their website:
https://creativemedicaltechnology.com/#1564122893003-81df70d5-84b0

Regarding their consistency of their flow of PRs...

From their March 11, 2020 PR regarding their immunotherapy for treatment called ImmCelz® for treatment of autoimmunity to preserve immune responses against cancer and infectious diseases:

https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-immcelz-adoptive-immunotherapy-product-301021407.html
PHOENIX, March 11, 2020 /PRNewswire/ -- Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named "IMMCELZ™".

"Current drugs treating autoimmunity act to suppress the immune system globally, thus increasing the risks of infections and cancers," said Dr. Thomas Ichim, Chief Scientific Officer of the Company and Co-Inventor of the technology. "In contrast, the IMMCELZ™ product specifically reprograms cells of the immune system in order to specifically stop attack against the body's own tissues, while preserving immune responses against cancer and infectious diseases."

From their Dec. 29, 2020 PR regarding their immunotherapy for treatment called ImmCelz® to reverse liver failure:

https://www.otcmarkets.com/stock/CELZ/news/story?e&id=1774305
PHOENIX, Dec. 29, 2020 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz® to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.

From their Dec. 16, 2020 PR regarding their immunotherapy for treatment called ImmCelz® for treatment of strokes:

https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-successful-application-of-immcelz-immunotherapy-for-treatment-of-stroke-301193921.html
PHOENIX, Dec. 16, 2020 /PRNewswire/ -- Creative Medical Technology Holdings Inc., (OTC – CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz® cell based immunotherapy for treatment of stroke.

v/r
Sterling